Figure 6
From: Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway
Afatinib conferred synergistic inhibition with 6AN via inhibition of EGFR pathway.
A) Genetic silencing of ERBB2, EGFR and mTOR respectively in NRAS WT myeloma cells showing no effect of mTOR inhibition in combination treatment; B) Blockade of ERBB2 in myeloma cells did not change downstream effector of mTOR but solely downstream of EGFR; C) Pharmaceutical inhibition of mTOR using rapamycin did not show synergy with 6AN as compared with Gefitinib and Afatinib; D) Scheme of how triple WT MM cells respond to EGFR inhibition and metabolic shift in response.
